South Korea · Delayed Price · Currency is KRW HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 358.44 billion. The enterprise value is 393.78 billion.
| Market Cap | 358.44B |
| Enterprise Value | 393.78B |
Important Dates
The last earnings date was Friday, December 19, 2025.
| Earnings Date | Dec 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 12.99 million shares outstanding. The number of shares has increased by 0.29% in one year.
| Current Share Class | 12.99M |
| Shares Outstanding | 12.99M |
| Shares Change (YoY) | +0.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.98% |
| Owned by Institutions (%) | 6.47% |
| Float | 8.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 33.82 |
| PS Ratio | 3.99 |
| PB Ratio | 10.58 |
| P/TBV Ratio | 10.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 1,125.97 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.56 |
| EV / Sales | 4.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -255.05 |
Financial Position
The company has a current ratio of 0.69, with a Debt / Equity ratio of 1.28.
| Current Ratio | 0.69 |
| Quick Ratio | 0.31 |
| Debt / Equity | 1.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | -28.05 |
| Interest Coverage | -15.23 |
Financial Efficiency
Return on equity (ROE) is -63.51% and return on invested capital (ROIC) is -19.29%.
| Return on Equity (ROE) | -63.51% |
| Return on Assets (ROA) | -14.05% |
| Return on Invested Capital (ROIC) | -19.29% |
| Return on Capital Employed (ROCE) | -61.47% |
| Revenue Per Employee | 324.11M |
| Profits Per Employee | -113.15M |
| Employee Count | 277 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.34 |
Taxes
In the past 12 months, HansBiomed has paid 2.32 billion in taxes.
| Income Tax | 2.32B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +247.98% in the last 52 weeks. The beta is 2.10, so HansBiomed's price volatility has been higher than the market average.
| Beta (5Y) | 2.10 |
| 52-Week Price Change | +247.98% |
| 50-Day Moving Average | 30,564.00 |
| 200-Day Moving Average | 14,741.20 |
| Relative Strength Index (RSI) | 41.34 |
| Average Volume (20 Days) | 459,282 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 89.78 billion and -31.34 billion in losses. Loss per share was -2,413.29.
| Revenue | 89.78B |
| Gross Profit | 51.51B |
| Operating Income | -27.89B |
| Pretax Income | -29.75B |
| Net Income | -31.34B |
| EBITDA | -22.78B |
| EBIT | -27.89B |
| Loss Per Share | -2,413.29 |
Balance Sheet
The company has 8.15 billion in cash and 43.31 billion in debt, giving a net cash position of -35.16 billion or -2,707.17 per share.
| Cash & Cash Equivalents | 8.15B |
| Total Debt | 43.31B |
| Net Cash | -35.16B |
| Net Cash Per Share | -2,707.17 |
| Equity (Book Value) | 33.89B |
| Book Value Per Share | 2,595.20 |
| Working Capital | -24.96B |
Cash Flow
In the last 12 months, operating cash flow was 318.34 million and capital expenditures -1.86 billion, giving a free cash flow of -1.54 billion.
| Operating Cash Flow | 318.34M |
| Capital Expenditures | -1.86B |
| Free Cash Flow | -1.54B |
| FCF Per Share | -118.88 |
Margins
Gross margin is 57.38%, with operating and profit margins of -31.07% and -34.91%.
| Gross Margin | 57.38% |
| Operating Margin | -31.07% |
| Pretax Margin | -33.14% |
| Profit Margin | -34.91% |
| EBITDA Margin | -25.37% |
| EBIT Margin | -31.07% |
| FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.29% |
| Shareholder Yield | -0.29% |
| Earnings Yield | -8.74% |
| FCF Yield | -0.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of -0.05 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.05 |
| Piotroski F-Score | 3 |